Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. Garay ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Welcome to Zymeworks fourth quarter and year-end 2024 results conference call and webcast. As a reminder, all participants are in listen-only mode and the conference is being recorded. (Operator ...

Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...

Bristol Myers Squibb is axing another 280 jobs as part of its $1.5 billion cost-cutting plan. The company is laying off 223 ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-b ...

MM+M today unveiled the 2025 classes of its Women of Distinction and Women to Watch. In its 10th year, the MM+M Women of Distinction and Women to Watch programs will celebrate 39 healthcare marketing ...